Literature DB >> 16831694

Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply.

Alessandro R Zanetti1, Luisa Romanò, Alessandra Zappá, Claudio Velati.   

Abstract

In Italy, as in most industrialized countries, the burden of hepatitis B has progressively declined in recent decades as a consequence of general improvements in hygiene and standard of living, the introduction of several public health measures, refinement in blood screening and the implementation of specific vaccination programmes. Universal hepatitis B vaccination for all infants and adolescents as well as individuals at increased risk has resulted in considerable progress towards prevention and control of HBV infection. The residual risk of transmitting blood-borne viruses through transfusion is currently very low. Nucleic acid testing can shorten the window period and, consequently, further reduce the risk of viral transmission. Blood donor screening for HCV by NAT was initiated in Italy in 2001 and became mandatory in June 2002. NAT for HIV is currently mandatory in four regions, not mandatory but almost universally performed in another thirteen regions, and not yet introduced in the remaining four regions. NAT for HBV is currently mandatory in four regions and under evaluation in the remaining. NAT for HBV may be a useful tool in detecting acute viral infections in the window phase as well as the occult infections. Its efficacy in improving the safety of blood supply is expected to be higher in countries with intermediate/high endemicity, where anti-HBc antibody screening cannot be routinely performed. There is agreement that, at present, the implementation of HBV DNA testing will not allow for discontinuation of screening for HBsAg.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831694     DOI: 10.1016/s1386-6532(06)80009-0

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  3 in total

1.  Prevalence of markers of hepatitis B virus infection or vaccination in HBsAg-negative subjects.

Authors:  Massimo De Paschale; Maria Teresa Manco; Luisa Belvisi; Bruno Brando; Stefania Latella; Carlo Agrappi; Paola Mirri; Arianna Gatti; Pierangelo Clerici
Journal:  Blood Transfus       Date:  2012-04-13       Impact factor: 3.443

2.  Automated nucleic acid amplification testing in blood banks: An additional layer of blood safety.

Authors:  Pragati Chigurupati; K Srinivasa Murthy
Journal:  Asian J Transfus Sci       Date:  2015 Jan-Jun

3.  Lamivudine treatment for severe acute HBV hepatitis.

Authors:  Andrea Lisotti; Francesco Azzaroli; Federica Buonfiglioli; Marco Montagnani; Flavio Alessandrelli; Giuseppe Mazzella
Journal:  Int J Med Sci       Date:  2008-10-23       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.